Brief
To understand the manufacturing and regulatory challenges surrounding specific complex generics and establish an understanding of potential players in the space.
Overview
Comprehensive mapping of the hurdles and barriers to entry in the complex generic space in the US and EU. Using deep secondary research, around 150 companies were screened in the initial phase of the project, which helped to create an overall competitive landscape for the target products.
Outcome
We created a threat-based analysis of the different players to highlight 5 key competitors that required follow-up deep-dive primary research into their capabilities and timelines.